10.1021/acs.molpharmaceut.5b00446.s002
G. Tosi
G.
Tosi
A. Vilella
A.
Vilella
P. Veratti
P.
Veratti
D. Belletti
D.
Belletti
F. Pederzoli
F.
Pederzoli
B. Ruozi
B.
Ruozi
M. A. Vandelli
M. A.
Vandelli
M. Zoli
M.
Zoli
F. Forni
F.
Forni
Exploiting Bacterial Pathways for BBB Crossing with
PLGA Nanoparticles Modified with a Mutated Form of Diphtheria Toxin
(CRM197): <i>In Vivo</i> Experiments
American Chemical Society
2015
CNS
NP
CRM 197
PLGA Nanoparticles Modified
BBB
DY
2015-10-05 00:00:00
Journal contribution
https://acs.figshare.com/articles/journal_contribution/Exploiting_Bacterial_Pathways_for_BBB_Crossing_with_PLGA_Nanoparticles_Modified_with_a_Mutated_Form_of_Diphtheria_Toxin_CRM197_i_In_Vivo_i_Experiments/2125807
Drugs
can be targeted to the brain using polymeric nanoparticles (NPs) engineered
on their surface with ligands able to allow crossing of the blood–brain
barrier (BBB). This article aims to investigate the BBB crossing efficiency
of polymeric poly lactide-<i>co</i>-glycolide (PLGA) NPs
modified with a mutated form of diphtheria toxin (CRM197) in comparison
with the results previously obtained using PLGA NPs modified with
a glycopeptide (g7-NPs). Different kinds of NPs, covalently coupled
PLGA with different fluorescent probes (DY405, rhodamine-B base and
DY675) and different ligands (g7 and CRM197) were tested <i>in
vivo</i> to assess their behavior and trafficking. The results
highlighted the possibility to distinguish the different kinds of
simultaneously administered NPs and to emphasize that CRM-197 modified
NPs and g7-NPs can cross the BBB at a similar extent. The analysis
of BBB crossing and of the neuronal tropism of CRM197 modified NPs,
along with their BBB crossing pathways were also developed. <i>In vivo</i> pharmacological studies performed on CRM197 engineered
NPs, loaded with loperamide, underlined their ability as drug carriers
to the CNS.